Glow peptide blend: the complete research guide to BPC-157 + TB-500 + GHK-Cu.

The glow peptide blend is three research compounds in one vial: BPC-157, TB-500 and GHK-Cu. Each has its own literature. The combination has none, and that's the single most useful thing we can tell you about it.

So this article is a per-constituent evidence review. The blend itself has never been tested as a unit. No trial, no case series, no published pharmacokinetics.

What exists is per-ingredient literature and a stacking rationale built on top of it. If you're deciding where to source the blend, our GLOW Blend sourcing guide covers CoA verification, ratio checks and pricing.

What is the glow peptide blend?

A glow peptide blend is a pre-mixed co-formulation of three compounds. Each grew popular on its own before the market packaged them together.

• BPC-157 — a synthetic 15-amino-acid peptide from a protective sequence in human gastric juice; the recovery community’s favorite. Full monograph: BPC-157 complete guide.
• TB-500 — the research-market name for thymosin beta-4 or its active fragment, an endogenous actin-binding peptide central to cell migration. Full monograph: TB-500 complete guide.
• GHK-Cu — the copper(II) complex of an endogenous tripeptide discovered in 1973, the most established dermal peptide, and what puts “glow” in the name. Full monograph: GHK-Cu complete guide.

Peptriva’s GLOW Blend follows the common market ratio: 10 mg BPC-157 + 10 mg TB-500 + 50 mg GHK-Cu, or 70 mg total in one lyophilized vial.

The logic of the trio is division of labor: repair signaling, cell migration, skin remodeling. Whether the combination does anything a single constituent doesn't is an open experimental question.

How does the glow blend work?

It works three separate ways, one per compound. There's no shared mechanism to describe, so here's each one, and then the reason the stack is put together at all.

BPC-157: angiogenesis and growth-factor signaling

BPC-157’s proposed mechanism is multifactorial rather than receptor-specific. The most cited pathway is VEGFR2 activation, with downstream nitric-oxide synthesis through Akt-eNOS.

A 2025 review by McGuire and colleagues proposes that pathway as the basis for repair in poorly vascularized tissue like tendon. Reviews also describe ERK1/2 activation and fibroblast stimulation.

No validated human receptor target exists. Nearly all of the mechanistic data is rodent and in vitro.

TB-500: G-actin sequestration and cell migration

Thymosin beta-4 is the best-characterized molecule in the vial. It binds monomeric G-actin in a 1:1 ratio, regulating the actin dynamics a cell uses to crawl into a wound.

Ying and colleagues documented downstream effects across skin trauma, corneal repair, hair-follicle regeneration and bone formation in 2023.

One market caveat you should hold on to. “TB-500” may mean full-length Tβ4 or only its active fragment, and suppliers don't always declare which one is in the vial.

GHK-Cu: copper delivery and matrix remodeling

GHK is endogenous to human plasma, and its levels fall with age. Dou and colleagues put the decline at roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60.

The histidine residue chelates copper(II) tightly. The resulting complex modulates collagen synthesis, glycosaminoglycan production and angiogenesis at injury sites.

In vitro work by Dymek and colleagues shows roughly 49% elastase inhibition. That's the mechanistic basis cited across the photoaging literature.

The stacking rationale, and its limit

Three mechanisms, three non-overlapping targets: growth-factor signaling, cytoskeletal migration, matrix remodeling. That non-redundancy is the entire theoretical case for the blend.

It has also never been tested. No study has measured whether the three compounds together beat any one of them alone, on any endpoint, in any species.

GLOW Blend

Three-compound blend 15 aa + 7 aa + 3 aa·Cu²⁺ 10/10/50 ratio

The same three compounds reviewed across the studies cited in this guide, with per-component mass-spec identity and lab-verified purity.

Shop GLOW blend

How is the glow blend used in research settings?

Reconstituted solution

The blend arrives as a single lyophilized cake at a fixed ratio. That's the format's defining property. It's convenient when 10/10/50 is what a study design calls for, and limiting when it isn't.

Topical formulations, GHK-Cu only

The well-supported route for GHK-Cu is topical, and that evidence does not transfer to the injectable format. Even topically, GHK-Cu penetrates the stratum corneum poorly and needs formulation help, per Dymek and colleagues.

Our cosmetic skin-peptides overview maps that landscape if the topical route is what you're after.

What does the research show, constituent by constituent?

BPC-157 has the largest preclinical footprint. A 2025 systematic review by Vasireddi and colleagues counted 36 studies, 35 preclinical and 1 clinical, with consistently positive outcomes in rodent injury models.

The human side is a 17-patient retrospective knee series from Lee and Padgett in 2021. 14 of 16 reachable patients, or 87.5%, reported subjective relief. There were no controls and no validated outcome measures.

Four of those patients received BPC-157 together with TB-500. That is the closest thing to combination data anywhere, and it's far too weak to conclude anything from. Most of the preclinical corpus also comes from a single research group in Zagreb.

TB-500 and thymosin beta-4 split into two stories. Full-length Tβ4 is a legitimate research molecule with human trials underway in ophthalmology.

The TB-500 sold for recovery is the other story. It has zero published human studies for orthopedic, athletic or aesthetic indications, a distinction a 2026 sports-medicine review by Mendias and Awan draws explicitly.

GHK-Cu is the best-evidenced constituent, for one route. Topically it has decades of cosmetic history and replicated wound-healing findings across independent groups, including Lee and colleagues in 2023.

Injectable GHK-Cu in humans is a different picture: no PubMed-indexed RCTs, 2020–2026. The blend inherits the injectable evidence tier, not the topical one.

GLOW Blend

70 mg ≥98% pure each Lyophilized

BPC-157 + TB-500 + GHK-Cu, 70 mg total (10/10/50) in one sterile lyophilized vial, with per-component identity testing. COA available with each lot.

Learn more

What are the side effects of the glow blend?

Nobody has collected them. The core problem here is absence of data, not documented harm. Total published human exposure to BPC-157 is fewer than 50 people, and TB-500 and injectable GHK-Cu have none at all for these indications.

• Commonly reported, anecdotal and unverified: injection-site redness or irritation; transient fatigue or lightheadedness.
• Less commonly reported: headache, nausea and dizziness in community reports, none of it systematically collected.
• Theoretical or serious: all three constituents promote angiogenesis, an unresolved concern around undetected vascularized tumors. GHK-Cu adds systemic copper redox chemistry with no injectable safety dataset behind it.
• Manufacturing, not molecules: the 2025 systematic review flags unregulated production and contamination as harm sources independent of the compounds themselves.

That last one is the one you can do something about. A batch-matched certificate of analysis is the only part of this picture with a checkable answer.

Is the glow blend legal?

In the US, yes, strictly as research-use-only reference material and not for human or veterinary use. None of the three constituents is FDA-approved as a drug, and the combination has no separate regulatory identity of its own.

BPC-157 sits on the FDA’s Category 2 list for 503A compounding, the bucket flagged for safety risks. GHK-Cu’s cosmetic history, under the name copper tripeptide-1, covers topical products only.

Our guide to US peptide legality covers the framework in full.

Is the glow blend banned in sport?

For a tested athlete it's a two-count violation in one vial. BPC-157 joined the WADA Prohibited List under S0, effective January 2022, per Józwiak and colleagues. Thymosin beta-4, and so TB-500, falls under S2.

GHK-Cu isn't explicitly listed. That's academic when the co-formulation already contains two prohibited compounds. The current list lives at wada-ama.org.

Frequently asked questions

What is the glow peptide blend, exactly?

A pre-mixed research formulation of BPC-157 at 10 mg, TB-500 at 10 mg and GHK-Cu at 50 mg, in one 70 mg lyophilized vial. The name comes from the aesthetics market, where GHK-Cu is the classic skin-glow copper peptide.

Does the glow blend actually work for skin?

Nobody knows. Topical GHK-Cu has replicated skin-remodeling evidence. Injectable GHK-Cu, which is the format in this blend, has zero human RCTs, and the combination has never been studied for anything.

Is the blend better than buying the three peptides separately?

It's more convenient, not better evidenced. A pre-mix guarantees the ratio and removes steps. It also locks you into 10/10/50 and rules out single-variable work.

What’s the difference between GLOW and the Wolverine blend?

Wolverine is the two-compound recovery pairing of BPC-157 and TB-500. GLOW adds 50 mg of GHK-Cu, which aims the stack at the skin and aesthetics research axis instead.

Is the glow peptide blend legal?

It's legal in the US as research-use-only material, and none of the constituents is a controlled substance. Selling it for human consumption is illegal. A tested athlete should treat it as prohibited, because it contains two WADA-listed compounds.

Why is the vial faintly blue?

Copper. GHK-Cu’s copper(II) complex tints solutions blue. Blue dye reproduces that color for pennies, so treat the tint as a consistency check and rely on the CoA. Our sourcing guide details what to check.